Willmott Dixon and Prime have started work on two new specialist facilities in partnership with University Hospital Southampton NHS Foundation Trust (UHS).
Situated on plot 2 of the Adanac Health and Innovation Campus in Southampton, the new multi-use facility, which is being funded by Macquarie Asset Management on behalf of the retirement specialist, Just Group, will comprise an aseptic pharmacy and sterile services department (SSD), with further flexible expansion space.
The pharmacy will act as an MHRA-licensed facility, with sterile medicines manufactured for UHS and other NHS providers in the region.
The SSD will sterilise surgical tools and equipment for use by UHS; with the services delivered at the new location by strategic provider, IHSS.
High demand
UHS is one of the largest acute teaching trusts in England and experiences a very high demand on its geographically-constrained site.
By working with Prime, through the Southampton Commercial Estates Development Partnership (CEDP), the trust has been able to unlock a number of complex estate challenges.
These new facilities will be the latest in a series of developments designed to create more space for the trust to expand.
Previous development on the site has produced a new entrance, retail space, and a staff car park.
The partners then worked together to create Adanac Health and Innovation Campus, providing additional expansion space with good proximity to the hospital and easy access to the motorway network.
To date, a multi-storey park-and-ride car park serving the hospital and Costa Coffee have been delivered at the new campus, and a remaining three plots are still to be developed.
A step forward
Ewan Forsyth, development director at Prime, said: “The construction of these facilities will be a major milestone in our partnership with UHS and a big step towards our shared goal of deepening the reputation of Southampton as a centre for medical excellence, preserving clinical space and enriching the local economy.”
James Allen, chief pharmacist at UHS, added: “This state-of-the-art facility will be a significant leap forward in our capacity to produce sterile, pre-prepared medicines.
“Sterile aseptically-prepared injectable products are vital in the care of patients in areas such as surgery, intensive care, and cancer services.
“As an MHRA-licensed unit, the facility will utilise advances in automation to produce products at scale, enhancing the capacity of patient pathways in UHS and NHS trusts in Hampshire and neighbouring healthcare systems.”